IPSEY - Ipsen - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

0.00

Cash

485.4M

Avg Qtr Burn

N/A

Short % of Float

0.00%

Insider Ownership

0.00%

Institutional Own.

0.01%

Qtr Updated

03/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Tazverik (Tazemetostat ) Details NHL (Non-Hodgkins Lymphoma), R/R FL (Relapsed or Refractory Follicular Lymphoma) and ES (Epithelioid Sarcoma)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Onivyde Details Cancer, Pancreatic cancer, Carcinoma	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Bylvay (Odevixibat) (ileal bile acid transport inhibitor) Details Alagille syndrome	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Sohonos (Palovarotene) Details Genetic disorder, Fibrodysplasia ossificans progressiva, Rare genetic disease	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Elafibranor (dual α,δ PPAR agonist) Details Cholestatic Liver Disease, Primary biliary cholangitis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Bylvay (Odevixibat) (ileal bile acid transport inhibitor) Details Progressive familial intrahepatic cholestasis	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tazemetostat + rituximab + lenalidomide Details Follicular lymphoma	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Cabometyx + atezolizumab Details Cancer, Prostate cancer	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Odevixibat (ileal bile acid transport inhibitor) Details Liver disease, Biliary atresia	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.